A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

The phase III placebo-controlled BRAVO study assessed laquinimod effects in patients with relapsing-remitting MS (RRMS), and descriptively compared laquinimod with interferon beta (IFNβ)-1a (Avonex ® reference arm). RRMS patients age 18–55 years with Expanded Disability Status Scale (EDSS) scores of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neurology 2014-04, Vol.261 (4), p.773-783
Hauptverfasser:	Vollmer, T. L., Sorensen, P. S., Selmaj, K., Zipp, F., Havrdova, E., Cohen, J. A., Sasson, N., Gilgun-Sherki, Y., Arnold, D. L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Brain research Drugs Endpoint Determination Female Humans Interferon Interferon-beta - adverse effects Interferon-beta - therapeutic use Male Medicine Medicine & Public Health Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Neurology Neuroradiology Neurosciences Original Communication Patients Pharmaceuticals Quinolones - adverse effects Quinolones - therapeutic use R&D Recurrence Research & development Risk Assessment Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!